Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma | Zendy

David A. Stempel | Zendy; Stanley J. Szefler | Zendy; Søren Pedersen | Zendy; Robert S. Zeiger | Zendy; Anne Yeakey | Zendy; Laurie A. Lee | Zendy; Andrew H. Liu | Zendy; Herman Mitchell | Zendy; Kenneth M. Kral | Zendy; Ibrahim Raphiou | Zendy; Barbara A. Prillaman | Zendy; Kathleen S. Buaron | Zendy; Suyong Yun Kirby | Zendy; Steven Pascoe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma

Author(s) -

David A. Stempel,

Stanley J. Szefler,

Søren Pedersen,

Robert S. Zeiger,

Anne Yeakey,

Laurie A. Lee,

Andrew H. Liu,

Herman Mitchell,

Kenneth M. Kral,

Ibrahim Raphiou,

Barbara A. Prillaman,

Kathleen S. Buaron,

Suyong Yun Kirby,

Steven Pascoe

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1606356

Subject(s) - salmeterol , fluticasone propionate , medicine , asthma , fluticasone , concomitant , anesthesia

Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research